First New York Securities’s Assembly Biosciences ASMB Stock Holding History

First New York Securities’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-150	Closed	-$34K	–	389
2013 Q4	$34K	Sell	150 -500	-77%	-$91K	0.02%	210
2013 Q3	$113K	Buy	+650	New	+$99.6K	0.05%	222

Other funds holding ASMB

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First New York Securities's ASMB Position: Q1 2014 in Review

First New York Securities sold out of Assembly Biosciences (ASMB) in Q1 2014, closing a stake of 150 shares — an estimated $34K sold.

First New York Securities first reported a position in ASMB in Q3 2013 and held it in 2 quarters. The position peaked at $113K in Q3 2013. 28 funds tracked by Wall St. Rank hold ASMB as of Q1 2014.

First New York Securities reported no remaining Assembly Biosciences position as of Q1 2014 after selling out during the quarter.
First New York Securities sold 150 Assembly Biosciences shares in Q1 2014, an estimated $34K.
First New York Securities first reported a position in Assembly Biosciences in Q3 2013 and held it in 2 quarters.
First New York Securities's Assembly Biosciences position peaked at $113K in Q3 2013.
28 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2014.

Based on First New York Securities's 13F filing for Q1 2014, filed 15 May 2014.